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Monoamine oxidase A (MAO-A) is an important target in the pathophysiology and therapeutics of
major depressive disorder, aggression, and neurodegenerative conditions. We measured the effect
of changes in MAO-A substrate on MAO-A binding in regions implicated in affective and
neurodegenerative disease with [
11C]-harmine positron emission tomography in healthy volunteers.
Monoamine oxidase A VT, an index of MAO-A density, was decreased (mean: 14%±9%) following
tryptophan depletion in prefrontal cortex (P<0.031), and elevated (mean: 17%±11%) in striatum
following carbidopa–levodopa administration (P<0.007). These findings suggest an adaptive role
for MAO-A in maintaining monoamine neurotransmitter homeostasis by rapidly compensating
fluctuating monoamine levels.
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Introduction
Monoamine oxidase A (MAO-A) has an important
role in processes such as monoamine neurotransmit-
ter metabolism and oxidation as well as the patho-
physiology of major depressive disorder (Meyer et al,
2006, 2009), cigarette smoking (Fowler et al, 1996),
and aggression (Alia-Klein et al, 2008). The MAO-A
site represents a central target for therapeutics of
Parkinson’s disease and major depressive disorder as
reflected by a recent resurgence in MAO-A inhibitor
development (Youdim et al, 2006). Since fluctuations
in monoamines can influence mood, motor control,
cognition, reward during substance abuse, and
predisposition to aggression through neurodevelop-
ment, there is a need to establish whether changes in
MAO-A substrate availability affect MAO-A levels
in the human brain.
To address this, we employed two well-established
paradigms of changing monoaminergic substrate
availability in an [
11C]-harmine positron emission
tomography (PET) study of healthy human subjects:
the first was the acute tryptophan depletion (ATD)
method to reduce availability of serotonin in pre-
frontal cortex (Lieben et al, 2004). The second was
sinemet (levi- and carbidopa) administration to
increase levels of striatal dopamine in Parkinson’s
disease (de la Fuente-Fernandez et al, 2001). We
chose [
11C]-harmine because it is reversible, selec-
tive, modeled in humans, has high affinity, no brain
penetrant metabolites, and its binding correlates
highly with known MAO-A density (Ginovart et al,
2006). To our knowledge, this is the first study to
investigate brain MAO-A binding following acute
monaminergic changes in any species.
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Participants
Nineteen healthy subjects were enrolled (mean age=25±8
years) and randomly assigned to three different groups: (1)
ATD (n=7), (2) sinemet (n=6), and (3) controls (n=6). All
were physically healthy, nonsmokers, and had no history
of neurotoxin use. Participants were screened using the
Structured Clinical Interview for DSM- to rule out any Axis I
disorders, the Structured Clinical Interview for DSM-IV for
Axis II disorders to rule out borderline and antisocial
personality disorder, and all underwent urine drug screening
on scan days. For each study participant, written consent was
obtained. Study and recruitment procedures were approved by
the Research Ethics Board for Human Subjects at the Centre for
Addiction and Mental Health, University of Toronto.
Protocol
The Hamilton Rating Scale for Depression was adminis-
tered at screening and on scan days. Each participant
underwent two PET scans: baseline and postmonoaminer-
gic challenge/depletion/no intervention. Behavioral and
mood symptoms were assessed with visual analog scale at
screening, and before and after each paradigm on scan
days. [
11C]-harmine PET scans were performed and plasma
samples of tryptophan and levidopa/carbidopa were taken
250 minutes after ATD and 150 minutes after intake of oral
single sinemet dose (200mg levodopa, 50mg carbidopa).
Image Acquisition and Analysis
[
11C]-harmine was of high specific activity (mean 715±
461s.d. mCi/mmol, 9.9±0.74mCi at injection time) and
administered as an intravenous bolus. An automatic blood
sampling system and manual samples were used to measure
arterial whole blood and plasma radioactivity (Ginovart
et al, 2006; Meyer et al, 2006, 2009). Arterial blood samples
were centrifuged, and whole unadulterated plasma samples
were injected onto a capture column packed with OASIS
resin. Highly polar metabolites and plasma proteins were
eluted with 1% CH3CN in H2O through a coincidence flow
detector (Bioscan Flow-Count, Washington DC, USA). Less
polar metabolites and [
11C]-harmine were washed onto an
high performance liquid chromatography (HPLC) column
(Phenomenex AquaC18, 5m; Phenomenex, Torrance, CA,
USA) and resolved using 30%CH3CN/70% H2O + 0.1N A.F.
pH4 as eluent. Positron emission tomography images were
obtained using an HRRT PET camera (full width at half
maximum, 3.1mm; 207 axial sections of 1.2mm, Siemens
Molecular Imaging, Knoxville, TN, USA).
For the region of interest method, each participant under-
went Magnetic Resonance Imaging (GE Signa 1.5-T scanner;
T1-weighted image; GE Medical Systems, Milwaukee, WI,
USA). Regions of interest were delineated on the magnetic
resonance imaging using a semiautomated algorithm based
on an region of interest template, and a probability of the
voxels belonging to the gray matter. Details of scanning,
radiotracer synthesis, and image analysis have been des-
cribed previously and for this study, the Logan method was
applied (Ginovart et al, 2006; Meyer et al, 2006, 2009),
details for plasma tracer analysis are given in Table 1. The
primary regions of interest were those for which each
monoamine manipulation, that is, tryptophan depletion and
sinemet administration, most consistently influence sub-
strate levels (i.e., prefrontal cortex (Lieben et al, 2004) and
striatum (de la Fuente-Fernandez et al, 2001), respectively).
Statistical Analysis
Both a repeated measures ANOVA (analysis of variance)
with MAO-A VT as the repeated measure, assessing the
effect of intervention and a paired, nonparametric
Wilcoxon-signed rank test comparing MAO-A VT before
and after each paradigm to the test–retest dataset were con-
ducted in each primary region of interest (ATD: prefrontal
cortex, carbidopa–levodopa challenge: striatum).
Results
As expected, tryptophan (TRP) plasma levels were in
the lower range (2.09±1.90mg/mL, normal range:
11.0 to 15.0mg/mL) following ATD. After ATD, MAO-
AV T decreased in all the subjects in the prefrontal
cortex, the primary region of interest, with the
range being from 3% to 30% of baseline (ANOVA:
P<0.031; nonparametric: P<0.018; see Figure 1).
Levodopa plasma levels and carbidopa levels were
in the expected range for a single dose (levodopa:
567±537ng/mL, carbidopa: 157±146ng/mL, nor-
mal range for total: 513 to 2,002ng/mL) 150 minutes
after dosing. After sinemet administration, MAO-A
VT increased in all subjects in the striatum, the
primary region of interest, with the range being from
6% to 34% (ANOVA: P<0.007; nonparametric:
P<0.028; see Figure 1).
There were no significant differences in MAO-AVT
values in prefrontal cortex or striatum in test/retest
conditions (prefrontal cortex: 5±3, striatum: 8%±5%
of baseline; see Figure 1). Groups did not differ signi-
ficantly regarding demographic characteristics (age,
gender, specific activity injected/injected mass of
radiotracer).
Table 1 Comparison of tracer properties in plasma in all three
groups
Percentage change of
parent fraction
a before
and after each manual
sample after minute
Carbidope/
levidopa
group
Acute
tryptophan
depletion
group
Test–retest
group
5minutes 12% 14% 5%
10minutes 8% 5% 2%
20minutes 3% 3% 2%
30minutes 2% 7% 2%
45minutes 1% 0.005% 1%
60minutes 4% 4% 7%
90minutes 1% 5% 5%
aParent fraction: percentage of parent (nCi/g) relative to metabolites (nCi/g).
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We found decreased MAO-A VT following ATD,
elevated MAO-A binding after dopamine precursor
administration, and no difference in test–retest con-
ditions (Figure 1). This is the first study to investigate
changes in MAO-A binding in the brain after changes
in endogenous neurotransmitter. These findings may
explain the resiliency of the human brain to environ-
mental conditions of fluctuating monoamines and
provide further insight into how therapeutics can
work in synergy or oppose this system.
The general perspective of the brain MAO-A turn-
over is that it is slow. The earliest time point that has
been assessed for change after hormonal manipula-
tions known to influence MAO-A synthesis was at
12 hours (Manoli et al, 2005). The present study
evaluated earlier time points and found changes in
MAO-A binding only 2.5 to 4 hours after substrate
manipulation. We acknowledge that 85% of the MAO-
AV T measured with [
11C]-harmine PET represents
specific binding to MAO-A, and changes in specific
binding can reflect changes in density or affinity.
However, to date, manipulations of MAO-A affinity
have not been described in the brain, tremendous
(>100%) changes in free and nonspecific binding to
account for the VT change are extremely unlikely and
it is well known that changes in the brain MAO-A
levels are highly correlated with MAO-A function
(Saura et al, 1992). Thus, the changes in MAO-A VT
can be viewed as a compensation opposing the acute
change in monoamine levels and as a mechanism to
regulate against acute monoamine fluctuations.
This is the first study to identify a change in the
brain MAO-A binding after acute substrate mani-
pulation. We are aware of one previous study
conducted in renal tissue: After 48 hours of incuba-
tion with dopamine, Pizzinat et al (2003) reported
an increase in MAO-A activity and protein in rat
mesangial cells, but not proximal tubule cells.
Greater MAO-A binding during monoamine precur-
sor supplement might offer some insight into the
limited clinical success of dietary monoaminergic
precursor supplements in treating major depressive
disorder (Mendlewicz and Youdim, 1980) and the
relatively temporary benefit of levodopa in Parkin-
son’s. In both circumstances, the administration of
the substrate should elicit an increase in MAO-A
binding that opposes the therapeutic intent of raising
monoamines. Interestingly, the most robust effects
on extracellular monoamines occur after direct MAO
inhibition (Ferrer and Artigas, 1994). The present
study also has implications for understanding neural
responsivity to ATD: The decrease in MAO-A
binding following ATD in healthy volunteers could
explain why sad mood is not observed in this group
whereas MAO-A binding is elevated in some groups
who are vulnerable to mood effects of ATD such
as recovered depressed subjects and SSRI-treated
depressed subjects (Neumeister et al, 2004). Future
work should consider whether the rise in MAO-A
binding is normative in people with a history of MDE
(major depressive episodes) after ATD.
[
11C]-harmine is increasingly being applied in
humans, due to its selectivity, reversibility, and other
favorable neuroimaging properties (Ginovart et al,
2006; Meyer et al, 2006, 2009). While some neuro-
imaging radiotracers have a property of changing
binding values in a manner consistent with occu-
pancy by endogenous neurotransmitter, our findings
are opposite to the endogenous neurotransmitter
occupancy model. This rules out lower endogenous
monoamine levels to explain why greater brain
MAO-A binding was found during MDE (Meyer
et al, 2006), during at risk states for MDE onset such
as recovery from MDE (Meyer et al, 2009) and early
postpartum (Sacher et al, 2010).
While the present study is limited by the indivi-
dual group size (n=6 to 7 per group), we report a
within-subject design, the effects are statistically
significant, the alteration in MAO-A binding is
present in every individual, and the direction is
consistent across the 12 subjects in relation to
depletion versus precursor administration. Regional
MAO-A VT values were in good agreement with
previous [
11C]-harmine PET studies (Meyer et al,
2006, 2009; Sacher et al, 2010), and our control group
shows very good test/retest reliability (Figure 1). The
measure of MAO-A used, an index of MAO-A
density called MAO-VT, reflects total binding, has
the advantage of being computationally efficient,
and is the most stable and least variable measure of
[
11C]-harmine binding. However, B15% of this
measure reflects free and nonspecific binding so
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Figure 1 Monoamine oxidase A distribution volumes (MAO-A
VT) changed in parallel with changes in endogenous substrate in
contrast to test/retest MAO-A VT values that did not change. In
healthy subjects, acute tryptophan depletion was associated
with a reduction in MAO-A VT, which ranged from 3% to 30%
and this effect was statistically significant (repeated measure
analysis of variance (ANOVA): P<0.031*; paired nonpara-
metric Wilcoxon-signed rank test, P=0.018*) for the primary
region of interest (prefrontal cortex). Oral administration of the
dopamine precursor (levodopa/carbidopa) was associated with
an increase in MAO-A VT, which ranged from 6% to 34% and this
effect was statistically significant (repeated measure ANOVA:
P<0.007**; paired nonparametric Wilcoxon-signed rank test,
P=0.028**) for the primary region of interest (striatum).
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underestimated (Ginovart et al, 2006). Also, while
it is theoretically possible that the changes in MAO-
AVT purely represent free and nonspecific binding,
this is unlikely since free and nonspecific binding
would have to change by a magnitude of 100% to
account for the change in MAO-A VT observed.
A change in MAO-VT may also reflect an alteration
in affinity of MAO-A in the direction of the change.
However, this would not change the interpretation of
our data as greater affinity for MAO-A following the
carbidopa–levodopa administration and less affinity
for MAO-A after the ATD paradigm would still
contribute to a dynamic role for MAO-A in a
compensating mechanism for protecting the human
brain from rapid monoamine fluctuation.
In conclusion, the present study suggests that
MAO-A levels are rapidly regulated by available
substrate in the human brain. The decline in MAO-A
binding following ATD can be interpreted as a
protective strategy against the effect of monoaminer-
gic loss in the healthy human brain, whereas the
acute increase in MAO-A binding following a
levodopa/carbidopa challenge may be a useful
strategy to compensate for a surge in monoamine
levels. This also explains why monoamine precursor
strategies have a limited duration of beneficial effect
and that the most robust manipulations of mono-
amine levels occur after MAO inhibition.
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